Intravitreal sustained-release ganciclovir.

Current treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome involves frequent intravenous administration of sodium ganciclovir that often results in unacceptable side effects. We have developed devices that release ganciclovir at rates of 2 micrograms/h and 5 micrograms/h in vitro. When implanted into the vitreous of rabbit eyes, mean intravitreal ganciclovir levels of 9 mg/L and 16 mg/L were maintained for more than 80 and 42 days, respectively. Devices were well tolerated, with no toxic effects attributable to the polymers used in the devices. This investigation indicates that these devices can maintain therapeutic levels of drug for extended periods and are well tolerated in the rabbit eye. They may prove useful in the clinical management of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.

[1]  W. Freeman,et al.  A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome. , 1984, American journal of ophthalmology.

[2]  M. Heinemann.  Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. , 1989, Archives of ophthalmology.

[3]  G. Friedland,et al.  Acquired immunodeficiency syndrome. , 1983 .

[4]  M. Gottlieb,et al.  Treatment of cytomegalovirus retinopathy with ganciclovir. , 1987, Ophthalmology.

[5]  C. Crumpacker,et al.  Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replication , 1984, Antimicrobial Agents and Chemotherapy.

[6]  E. R. Büchi,et al.  Long-term intravitreal ganciclovir for cytomegalovirus retinitis in a patient with AIDS. Case report. , 1988, Archives of ophthalmology.

[7]  O. Laskin,et al.  Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethyl guanine. , 1986, American journal of ophthalmology.

[8]  D. Longo,et al.  Ophthalmic involvement in acquired immunodeficiency syndrome. , 1984, Ophthalmology.

[9]  E. Stool,et al.  Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. , 1988, Ophthalmology.

[10]  E. Huang,et al.  Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro , 1983, Antimicrobial Agents and Chemotherapy.

[11]  J. C. Martin,et al.  9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. , 1983, Journal of medicinal chemistry.

[12]  J. Phair,et al.  Ophthalmologic findings in acquired immune deficiency syndrome (AIDS). , 1984, Archives of ophthalmology.

[13]  W. Freeman.  Intraocular antiviral therapy. , 1989, Archives of ophthalmology.

[14]  R D Yee,et al.  Acquired immune deficiency syndrome. Ocular manifestations. , 1983, Ophthalmology.

[15]  W. Freeman,et al.  Cytomegalovirus retinitis and response to therapy with ganciclovir. , 1987, Ophthalmology.

[16]  R. Ramsay,et al.  Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results. , 1989, Ophthalmology.

[17]  J. Pepose,et al.  Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease. , 1985, Ophthalmology.

[18]  H. Balfour,et al.  Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. , 1987, American journal of ophthalmology.

[19]  W. Culbertson.  Infections of the retina in AIDS. , 1989, International ophthalmology clinics.